Irritability Associated with Autistic DisorderĪBILIFY is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode.
#ABILIFY MEDICATION TRIAL#
Maintenance efficacy was demonstrated in one monotherapy maintenance trial and in one adjunctive maintenance trial in adults.Īdjunctive Treatment of Major Depressive DisorderĪBILIFY is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Maintenance Treatment of Bipolar I DisorderĪBILIFY is indicated for the maintenance treatment of bipolar I disorder, both as monotherapy and as an adjunct to either lithium or valproate. Efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults. Efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). Maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents.Īcute Treatment of Manic and Mixed EpisodesĪBILIFY is indicated for the acute treatment of manic and mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate. The efficacy of ABILIFY was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). News in Media Published Studies Curr't Clinical TrialsĪBILIFY is indicated for the treatment of schizophrenia. Summary Description and Clinical Pharmacology Indications and Dosage Warnings and Precautions Side Effects and Adverse Reactions Drug Interactions, Overdosage, Contraindications, Other Rx Info Active Ingredients User Ratings / Reviews Side Effect Reports
Rx drug information, pharmaceutical research, clinical trials, news, and more Abilify (Aripiprazole) - Indications and Dosage
0 kommentar(er)
